UK markets closed

Zealand Pharma A/S (0NZU.L)

LSE - LSE Delayed price. Currency in DKK
Add to watchlist
126.80+8.08 (+6.81%)
At close: 05:30PM BST
Full screen
Previous close118.72
Open123.20
BidN/A x N/A
AskN/A x N/A
Day's range123.20 - 124.50
52-week range123.20 - 124.50
Volume11,884
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Zealand Pharma Announces Financial Results for the First Half of 2022

    Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial Results for the First Half of 2022 Copenhagen, DK and Boston, MA, U.S. August 11, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced financial results for the first half of 2022 and provided a corporate update. Key strategic objectives achieved Adam Steensberg, President an

  • Globe Newswire

    Updated notice to holders of ADSs regarding termination of Deposit Agreement

    NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”)EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS (“ADRs”)REPRESENTING DEPOSITED ORDINARY SHARES OF:ZEALAND PHARMA A/S ONE ADS REPRESENTS ONE COMMON SHARECUSIP: 98920Y304 AND UNDERLYING ISIN: DK0060257814 Company announcement – No. 33 / 2022 Copenhagen, DK and Boston, MA, August 8, 2022 – Zealand Pharma A/S (“Zealand” or the “Company”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-headquartered biotechnology company focused on the discovery and

  • Globe Newswire

    Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market

    Company announcement – No. 32 / 2022 Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market Zealand will consolidate trading to Nasdaq Copenhagen, the company’s primary and most liquid stock exchangeDecision is part of Zealand’s refocused strategy to prioritize R&D and streamline corporate operations Copenhagen, DK and Boston, MA, U.S. August 8, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnol